Dr. Anil Narasimha is an accomplished scientist and founder in the field of personalized medicine. He co-founded Mekonos in 2017 to come up with a platform to automate delivery of payloads into fragile cell types while remaining precise and scalable. Prior to Mekonos, Anil completed his PhD at UC San Diego before moving to Stanford University to become a postdoctoral fellow in Dr. Michael Snyder's laboratory. There, he was introduced to cell and gene therapy and identified some of the pitfalls associated with it, including the lack of automation and precision when it came to delivering payloads into primary cells. His goal is to utilize his platform to make cell and gene therapies more accessible.
Ex-vivo Silicon-based Delivery of Macromolecules into Cells
At Mekonos, we are developing a platform for delivery of payloads into cells in a precise, efficient, and automated manner. We take advantage of scalable silicon technology to create a method that is advantageous for complex gene editing, targeted delivery, and dose control at the single cell level.
Vanessa Soros, Graphite Bio